These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 8713776

  • 1. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
    Shapiro AD, Ragni MV, Lusher JM, Culbert S, Koerper MA, Bergman GE, Hannan MM.
    Thromb Haemost; 1996 Jan; 75(1):30-5. PubMed ID: 8713776
    [Abstract] [Full Text] [Related]

  • 2. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE.
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
    Djulbegovic B, Marasa M, Pesto A, Kushner GM, Hadley T, Joseph G, Goldsmith G.
    Am J Hematol; 1996 Feb; 51(2):168-70. PubMed ID: 8579061
    [Abstract] [Full Text] [Related]

  • 4. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies.
    Mauser-Bunschoten EP, Kleine Budde I, Lopaciuk S, Koopman MM, Van Der Meer FJ, Novàkovà IR, Ypma P, Van Der Linden PW, Windyga J, Strengers PF.
    Haemophilia; 2011 May; 17(3):439-45. PubMed ID: 21362109
    [Abstract] [Full Text] [Related]

  • 5. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N, Karges HE, Weidmann E.
    Dev Biol Stand; 1987 May; 67():303-10. PubMed ID: 3038638
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of OCTANINE F in children with haemophilia B.
    Klukowska A, Laguna P, Svirin P, Shiller E, Vdovin V.
    Haemophilia; 2008 May; 14(3):531-8. PubMed ID: 18355266
    [Abstract] [Full Text] [Related]

  • 7. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañes M, Paez A.
    Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
    [Abstract] [Full Text] [Related]

  • 8. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J, Peynet J, Chambost H, Négrier C, Briquel ME, Claeyssens S, Derlon-Borel A, Guérois C, Caron C, Scherrmann JM, Debray M, Bridey F.
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [Abstract] [Full Text] [Related]

  • 9. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A, Laurian Y, Rothschild C, Navarro R, Guérois C, Gay V, Durin A, Peynet J, Sultan Y.
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [Abstract] [Full Text] [Related]

  • 10. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K, Schwarz P, Kunschak M.
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract] [Full Text] [Related]

  • 11. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Cabrera N, Aznar JA, Woodward MK, Páez A.
    Haemophilia; 2011 Jul; 17(4):590-6. PubMed ID: 21299747
    [Abstract] [Full Text] [Related]

  • 12. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran).
    Mansour-Ghanaei F, Fallah MS, Shafaghi A, Yousefi-Mashhoor M, Ramezani N, Farzaneh F, Nassiri R.
    Med Sci Monit; 2002 Dec; 8(12):CR797-800. PubMed ID: 12503038
    [Abstract] [Full Text] [Related]

  • 13. Radioactive synoviorthesis in patients with hemophilia with factor inhibitor.
    Löfqvist T, Petersson C, Nilsson IM.
    Clin Orthop Relat Res; 1997 Oct; (343):37-41. PubMed ID: 9345203
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA, Cabrera N, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañés M, Páez AM, Lissitchkov T.
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [Abstract] [Full Text] [Related]

  • 15. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Nugent K, Vigliani G, Brennan A, Luk A, Pierce GF, B-LONG Investigators.
    N Engl J Med; 2013 Dec 12; 369(24):2313-23. PubMed ID: 24304002
    [Abstract] [Full Text] [Related]

  • 16. Rituximab for adolescents with haemophilia and high titre inhibitors.
    Fox RA, Neufeld EJ, Bennett CM.
    Haemophilia; 2006 May 12; 12(3):218-22. PubMed ID: 16643204
    [Abstract] [Full Text] [Related]

  • 17. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
    Serban M, Skotnicki AB, Colovic M, Jinca C, Klukowska A, Laguna P, Wolf DM.
    Haemophilia; 2012 Mar 12; 18(2):175-81. PubMed ID: 21812863
    [Abstract] [Full Text] [Related]

  • 18. Preclinical studies of a monoclonal antibody-purified factor IX, Mononine.
    Hrinda ME, Huang C, Tarr GC, Weeks R, Feldman F, Schreiber AB.
    Semin Hematol; 1991 Jul 12; 28(3 Suppl 6):6-14. PubMed ID: 1780768
    [No Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP, Posthouwer D, Fischer K, van den Berg HM.
    Haemophilia; 2007 Nov 12; 13(6):697-700. PubMed ID: 17877729
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.